First patient to be administered Oncobax® AK, a live bacterial product based on a specific strain found in the gut microbiota, at Institut de Cancérologie Strasbourg Europe (ICANS) in Strasbourg, France60 patients across France and Belgium to take part in a trial which aims to assess the toxicity and efficacy of the.
EverImmune appoints scientific advisory board of four international experts in cancer immunotherapy and oncobiotics (the study of interactions between the microbiome and cancer cells)As specialists in oncology, microbiology and immunology, they will support the company in developing its product portfolioVillejuif-Gr.
EverImmune, a biotech based near Paris, and specialized in the development of live biotherapeutic products in the field of microbiota oncology, has raised €5m (US$5.7m) in a Series A funding round from undisclosed private investors.
Villejuif, near Paris, France, November 30, 2021 – EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from undisclosed private investors. EverImm.